

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Octreotide Agents

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Sandostatin (octreotide acetate)	N/A
Bynfezia (octreotide acetate) Pen	1 pen per 14 days
**Sandostatin LAR Depot (octreotide acetate) 10mg, 30mg Kit	1 kit per 28 days
**Sandostatin LAR Depot (octreotide acetate) 20mg Kit	2 kits per 28 days

****Applicable Medicaid Markets – Sandostatin LAR pharmacy policy only applicable to VA and Amerigroup Medicaid only**

APPROVAL CRITERIA

Requests for Bynfezia Pen, Sandostatin, or Sandostatin LAR Depot (octreotide) may be approved for individuals who meet the following criteria:

- I. Individual has a diagnosis of acromegaly; **AND**
 - II. Individual has had an inadequate response to any of the following:
 - A. Surgical resection; **OR**
 - B. Pituitary irradiation; **OR**
 - C. Bromocriptine mesylate at maximally tolerated doses;
- OR**
- III. Surgery and/or radiotherapy is not an option;
- OR**
- IV. Individual has a diagnosis of carcinoid tumors and is using for any of the following:
 - A. Metastatic carcinoid tumors to suppress or inhibit severe diarrhea and flushing episodes associated with the disease; **OR**
 - B. Prophylactic administration prior to biopsy in an individual with a suspected functioning carcinoid tumor (NCCN 2A); **OR**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

- C. Prophylactic administration prior to induction of anesthesia in an individual with a functional carcinoid tumor (AHFS); **OR**
- D. Prophylactic administration perioperatively to a surgical procedure in an individual with a functional carcinoid tumor (AHFS);

OR

- V. Individual has a diagnosis of neuroendocrine tumors and is using for any of the following:
 - A. For the management of unresectable locoregional disease or distant metastasis (NCCN 2A); **OR**
 - B. For the treatment of the profuse watery diarrhea associated with VIPomas; **OR**
 - C. For the treatment of underlying hypergastrinemic Zollinger-Ellison syndrome (NCCN 2A); **OR**
 - D. Prophylactic treatment prior to surgery for gastrinoma (NCCN 2A);

OR

- VI. Individual is using for bleeding Gastroesophageal (GE) varices and the following criteria are met:
 - A. GE varices are associated with liver disease (Banares 2002, Corley 2001); **AND**
 - B. Octreotide acetate is used in combination with endoscopic therapy or alone if endoscopic therapy is not immediately available (Garcia-Tsao 2007);

OR

- VII. Individual is using for central nervous system (CNS) meningiomas that are surgically inaccessible, recurrent, or progressive and is not a candidate for further radiation therapy (NCCN 2A);

OR

- VIII. Individual is using for chemotherapy or radiation-induced diarrhea that is unresponsive to conventional antidiarrheal medications (such as atropine, diphenoxylate, and loperamide) (NCCN 2A);

OR

- IX. Individual is using for malignant bowel obstruction to manage gastrointestinal (GI) symptoms (e.g. nausea, pain, or vomiting) (NCCN 2A);

OR

- X. Individual is using for thymic carcinoma or thymoma with or without prednisone (NCCN 2A);

OR

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

- XI. Individual is requesting Sandostatin for rapid relief of symptoms or for breakthrough symptoms in individuals taking long-acting octreotide acetate when any of the criteria are met for the above uses (NCCN 2A).

Requests for Bynfezia Pen, Sandostatin, or Sandostatin LAR Depot (octreotide) may **not** be approved for any of the following:

- I. Individual is using for the treatment of chylothorax; **OR**
- II. Individual is using for the treatment of Diarrhea associated with acquired immunodeficiency syndrome; **OR**
- III. Individual is using for the treatment of gastrointestinal diseases(e.g. bleeding from vascular malformations, gastroparesis, pancreatitis, prevention of postoperative complications following pancreatic surgery, short bowel syndrome, or upper GI bleeding); **OR**
- IV. Individual is using for the treatment of Graves' ophthalmopathy; **OR**
- V. Individual is using for the treatment of hypothalamic obesity; **OR**
- VI. Individual is using for the treatment of other carcinomas (e.g. advanced breast cancer, hepatocellular cancer, or prostate cancer); **OR**
- VII. Individual is using for the treatment of polycystic kidney disease.

Key References:

1. Archimandritis A, Tsirantonaki M, Tryphonos M, et al. Ranitidine versus ranitidine plus octreotide in the treatment of acute non-variceal upper gastrointestinal bleeding: a prospective randomised study. *Curr Med Res Opin.* 2000; 16(3):178-183.
2. Bajetta E, Procopio G, Ferrari L, et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. *Cancer.* 2002; 94(2):299-304.
3. Brown C, Subramanian V, Wilcox CM, Peter S. Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. *Dig Dis Sci.* 2010; 55(8):2129-2134.
4. Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. *Lancet.* 2013; 382(9903):1485-1495.
5. Chapman JA, Costantino JP, Dong B, et al. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. *Breast Cancer Res Treat.* 2015; 153(2):353-360.
6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
7. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 4, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

8. Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. *Cochrane Database Syst Rev.* 2010;(9):CD006388.
9. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
10. Edmunds MC, Chen JD, Soykan I, et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. *Aliment Pharmacol Ther.* 1998; 12(2):167-174.
11. Friedlander TW, Weinberg VK, Small EJ, et al. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. *Urol Oncol.* 2012; 30(4):408-414.
12. Fujita T, Daiko H. Efficacy and predictor of octreotide treatment for postoperative chylothorax after thoracic esophagectomy. *World J Surg.* 2014; 38(8):2039-2045.
13. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. *J Am Soc Nephrol.* 2010; 21(6):1052-1061
14. Ismail NA, Gordon J, Dunning J. The use of octreotide in the treatment of chylothorax following cardiothoracic surgery. *Interact Cardiovasc Thorac Surg.* 2015; 20(6):848-854.
15. Jia WD, Zhang CH, Xu GL, et al. Octreotide therapy for hepatocellular carcinoma: a systemic review of the evidence from randomized controlled trials. *Hepatogastroenterology.* 2010; 57(98):292-299.
16. Junquera F, Saperas E, Videla S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. *Am J Gastroenterol.* 2007; 102(2):254-260.
17. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
18. Loyaga-Rendon RY, Hashim T, Tallaj JA, et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. *ASAIO J.* 2015; 61(1):107-109.
19. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. *J Clin Endocrinol Metab.* 2003; 88(6):2586-2592.
20. Nehra V, Camilleri M, Burton D, et al. An open trial of octreotide long-acting release in the management of short bowel syndrome. *Am J Gastroenterol.* 2001; 96(5):1494-1498.
21. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2019 National Comprehensive Cancer Network, Inc. Available at: [NCCN.org](http://www.nccn.org). Updated periodically.
22. Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. *J Clin Rheumatol.* 2007; 13(3):119-123.
23. Panel on opportunistic infections in HIV-infected adults and adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Last updated May 29, 2018. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
24. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. *Kidney Int.* 2005; 68(1):206-216.
25. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. *N Engl J Med.* 1991; 325(21):1461-1467.
26. Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. *J Clin Endocrinol Metab.* 2006; 91(12):4817-4824.
27. Swanson MS, Hudson RL, Bhandari N, et al. Use of octreotide for the management of chyle fistula following neck dissection. *JAMA Otolaryngol Head Neck Surg.* 2015; 141(8):723-727.
28. Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. *Can J Gastroenterol.* 2006; 20(3):171-178.
29. Testoni D, Hornik CP, Neely ML, et al. Best Pharmaceuticals for Children Act - Pediatric Trials Network Administrative Core Committee. Safety of octreotide in hospitalized infants. *Early Hum Dev.* 2015; 91(7):387-392.
30. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. *Dig Dis Sci.* 1995; 40(9):1892-1901.
31. Xu W, Zhou YF, Xia SH. Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis. *Hepatogastroenterology.* 2013; 60(126):1504-1508.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.